Cure My Disease

Don't miss your cure!

 Log in / Sign up

Magic mushroom compound tested for meth addiction – but trial stopped early

NCT ID NCT05322954

Terminated Symptom relief Sponsor: University of Wisconsin, Madison Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether psilocybin, the active ingredient in magic mushrooms, is safe and feasible for people with methamphetamine use disorder. Only 5 participants were enrolled, and the trial was terminated early, so the results are very limited. The goal was to see if psilocybin could be given safely alongside behavioral support.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
psilocybin
What this could lead to
If it works, this could point toward a new way to help people reduce methamphetamine use.
What could go wrong
This was a very early, tiny trial (only 5 participants) that was terminated early, so we have little data. Psilocybin can cause temporary anxiety, confusion, or high blood pressure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHEMICALLY-INDUCED DISORDERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Chemically-Induced Disorders methamphetamine dependence substance-related disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHEMICALLY-INDUCED DISORDERS METHAMPHETAMINE USE DISORDER STIMULANT USE DISORDER SUBSTANCE USE DISORDERS SUBSTANCE-RELATED DISORDERS

Contacts and locations

Locations

  • University of Wisconsin

    Madison, Wisconsin, 53705, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.